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Hexahydro-sila-difenidoJ and eight analogues behaved as simple cumpetitive inhibitors of eHJN·methyl·scopoJamine binding to 
homogenates frorn human neuroblastoma NB-OK 1 cells (MI sites), rat heart (M 2 sites), rat pancreas (M3 sites), and rat striatum 
'B' sites (M4 sites). Pyrrolidino- and hexamethyleneimino analogues showed the same sekctivity profile as the parent compound. 
Hexahydro-sila-difenidol methiodide and the methiodide of p-fluoro-hexahydro·sila-difenidol had a fügher affinity but a lower 
selectivity than the tertiary amines. Compounds containing a p·methoxy, p-chJoro or p-fluoro substituent in the phenyl ring of 
hexahydro-sila-difenidol showed a qualitative)y similar selectivity profile as the parent compound (i.e., MI= M 3 = ;"~ 4 ::;.. M 2 j, but 
up to 16-fold lower affinities. o-Methoxy-hexahydro-sila-difenidol has a lower affinity than hexahydro-sila-difeni.:!o! at the four 
binding sites. lts selectivity profile (M 4 > M 1, M 3 > M 2 ) was different from hexahydro-sila-difenidol. 
Replacement of the centrat silicon atom of hexahydro-sila-difenidol, p-fluoro-hexahydro-sila-difenidol and thdr quatemary 
(N-methylated) analogues by a carbon atom did not change their binding affinities significantly. The iour muscarinic receptors 
showed a higher affinity for the (R)- than for the (S)-enantiomers of hexahydro-difenidol, p-fluorohexahydro-difenidol and their 
methiodides. The stereoselectivity varied depending on the receptor subtype and drug considered. 
Musearlnie receptor subtypes (MI• M 2, M 3, and (putative) M 4 ); Muscarinic receptor antagonists (selective); 
Hexahydro-sila-difenidol analogues; p-Fluoro-hexahydro-sila-difenidol: Stereoselecti"·ity (at muscarinic receptors) 
1. Introducdon 
Musearlnie acetylcholine receptors are currently di-
vided into at least three pharmacologi.cally defined sub-
types: M 1, M 2 (M 2a) and M 3 (M2Jl) receptors (for 
recent reviews, see Mutschier et al., 1987; 1988; 
Mitchelson, 1988; Levine and Birdsall, 1989). M 1 recep-
tors are typically found in neuronal tissues (central 
nervous system and autonomic ganglia), M 2 receptors 
in lower brain areas (cerebellum) and heart, and M 3 
receptors in secretory glands and smooth muscle. This 
classification is based mainly on the different affinities 
of musearlnie receptor subtypes for antagonists such as 
pirenzepine (M1 > M 3 ~ M 2 ) (Hammer et al.. 1980; 
Eltze et al .. 1988; Waelbroeck et al., 1988), AF-DX 116 
(Giachetti et al., 1986; Hammer et al., 1986; Micheleui 
et al., 1987), methoctramine (Melchiorre et al., 1987; 
Giraldo et al., 1988) (M 2 > M1 > M 3) and hexahydro-
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sila-difenidol (Lambrecht et al., 1987, 1989b; 
\Vaelbroeck et al.. 1987a; Waelbroeck et aL. 1989a; 
Lazareno and Roberts, 1989) (M3 ~ M 1 > M 2 ). Re-
cently a fourth subtype with high affinity for 
methoctramine and himbacine. as weil as for 
hexahydro-sila-difenidol and 4-diphenylacetoxy-N-
methylpiperidine methiodide has been identified in 
NG108-15 cells (Michel et al., 1989} and rat forebrain 
(Waelbroeck et al., 1990). The antagonist binding prop-
erties, or the tissue and cell tine distribution of these 
four pharmacologically defined subtypes correspond 
closely to that of the recently cloned receptor proteins 
m1 to m4 (Akiba et al., 1988~ Banner et al., 1987; 
Peraha et al.. 1987; Buck.ley et al., 1989; Dörje et a1., 
1990; Wess et al., in press). 
Using the nonselective antagonist eHJN-methyl-
scopolamine (eH]NMS) as radioligand. we previously 
demonstrated that over 80% of the muscarinic receptors 
in the human neuroblastoma NB-OK 1 cellline are of 
the M1 subtype (Waelbroeck et al., 1988). tbat receptors 
in rat heart are of the M2 subtype (Waelbroeck et al., 
1987a,b), receptors in rat pancreas beleng to the M3 
subtype (Waelbroeck et al .• 1987a). and that 85% of tbe 
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'B' binding sites in rat striatum (Waelbroeck et al.. 
1987b) can be considered as putative M4 receptors 
(Waelbroeck et al., 1990). 
The first aim of the present study was to examine the 
binding properlies of eight hexahydro-sila-difenidol 
analogues structuralJy modified in the cyclic amino 
group and the phenyl ring (fig. 1). using the four 
above-mentioned test systems. The functional anti-
musearlnie properlies of these muscarinic antagonists 
have been reported recently (Lambrecht et al., 1989a.b; 
Waelbroeck et al., 1989a). All these silicon compounds 
possess a center of chirality. They were used as race-
mates since indications were found that silanols 
(R 3Si0H) may racemize in aqueous so1ution (Tacke et 
al., 1987). The s~cond goal of this study was to investi~ 
gate the importance of absolute configuration for bind~ 
ing of hexahydro-sila-difenidol analogues to musearlnie 
receptors. To achieve this goal we used the configura-
tionally stable (R)- and (S)-enantiomers of the four 
carbon analogues of 1 b, 4b, Sb and 9b ( -+ compounds 
la. 4a, 8a and 9a, Fig. 1). The functional antimuscarinic 
properties of the (R)- and (S)-enantiomers of 
hexahydro-difenidol (la), p-fluoro-hexahydro-difenidol 
(8a) and their methiodides 4a and 9a have been re-
ported elsewhere (Tacke et al., 1989; Feifel et al.. 1990; 
Lambrecht et al., 1990). 
Formula 
Formula 
No. 
2. Materials and methods 
2.1. Ce/1 and tissue preparation:; 
Human NB-OK 1 neuroblastoma Cl!lls (a generaus 
gift from Dr. Yanaihara, Shizuoka, Japan) were main-
tained in RPMI-1640 medium, enriched with 100 U/ml 
penicillin, 100 l'g/ml Streptomycin and 10% fetal calf 
serum (from Gibco, Gent, Belgium). Twice a week, the 
cells were detached by trypsin-EDTA (Gibco, Gent, 
Belgium) and divided in thirds. For eH]NMS binding 
experiments, the cells were harvested using a 20 mM 
sodium phosphate buf!er enriched with 1 mM EDTA 
and 150 mM NaCI (pH 7.4}, centrifuged at 500 g for 5 
min, resuspended and homogenized in 20 mM Tris-HCI 
buffer enriched with 5 mM MgCI 2 (pH 7 .5) in a glass-
Teflon homogenizer, and then stored in liquid nitrogen 
until use. 
For cardiac homogenates, male Wist.ar albino rats 
(200-250 g) were decapitated, the beart immediately 
removed and rinsed in 150 mM Na.Cl. The homogeniza-
tion buffer contained 10 mM Tris-HCl (pH 7.5) and 250 
mM sucrose. Each heart was homogenized in 2 ml of 
this buffer with an Ultraturrax homogenizer (maximal 
speed for 5 s at 4 ° C) followed by further addition of 13 
ml of buffer, and seven up and down strokes in a 
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Fig. 1. Chemical structure of the carbon,lsilicoo analogues, hexahydro-difenidol (la), hexahydro-sila-difenidol (lb) and their derivatives (2), (3), 
hexahydro-diferudol methiodide (4a), hexahydro-sila-difenidol methiodide (4b), p-methoxy-hexahydro-sila-difenidol (5), o-methoxy-hexahydro-
sila-difenidol (6). p<hloro-be.,.··hvdro-::sl~-rii!c:::&i~ü: (7); p-fluoro-hexahydro-difeni<iol (8a), p-fluorohexahydro-sila-d.ifenidol (8b), p-fluoro-hexa-
bydro-difewlol methiodide {9a) and p-fluoro-bexahydro-sila-difenidol methiodide (9b). 
g1ass-Teflon homogenizer (at 4 o C). The homogenate 
was fittered on two layers of medical gauze and either 
used fresh, or stored in liquid nitrogen until use. 
For rat brain cortex and striatum homogenates the 
brain was immediately removed and dissected. The 
cortex and striatum were homogenized in 15 and 2 ml, 
respectively, of 20 mM Tris-HCJ buffer (pH 7.5) en-
riched with 250 mM sucrose, with a glass-Teflon homo-
genizer, and stored in liquid nitrogen until use. These 
homogenates were diluted 20-fold with the homogeniza-
tion buffer before use for eHJNMS binding experi-
ments. 
For rat pancreas homogenates the organ was im-
mediately removed, minced with scissors and homoge-
nized in a glass-Teflon homogenizer ( seven up and 
down strokes at 4 o C) in a solution containing 300 mM 
sucrose, 0.2 mgjml bacitracin and 500 kallikrein inhibi-
tor U /ml of Trasylol (Bayer, Brussels, Belgium). The 
resulting homogenate was immediately filtered on two 
layers of medical gauze and diluted ll~fold with the 
incubation buffer made of 66 mM sodium phosphate 
(pH 7.4) enriched with 2.6 mM MgCI 2, 500 kallikrein 
inhibitor U jml of Trasylol, 0.2 mg/mJ hacitracin and 
13 mg/ml bovine serum albumin. 
2.2. [3H]NMS binding experiments 
eHJNMS binding was measur'!d at 25 o C in a total 
volume of 1.2 ml using the following incubation buffer: 
50 mM sodium phosphate (pH 7.4) enriched with 2 mM 
MgC1 2, 1% bovine serum albumin (except when indi-
cated) and the indicated tracer and drug concentrations. 
Addition of bovine serum albumin to the incubation 
buffer increased eH]NMS binding very slightly (by at 
most 10-15%) and improved the reproducibility of 
duplicates in our filtration assays. In binding experi-
ments on pancreas homogenates, we also added Trasy-
lol and bacitracin (see above) to further inhibit proteo-
lytic activity. Bovine serum albumin was an essential 
ingredient in pancreas binding studies, since the binding 
capacity of pancreas homogenates disappeared within 
40 min at room temperature if this protein was omitted 
from the buffer, but was maintained over 90% for at 
least 4 hin its presence. 
To terminate the incubation, each sample was di1uted 
with 2 ml of ice~cold 50 mM sodium phosphatc buffer 
(pH 7.4) and filtered on GF jC glass-fiber filters (What-
man, Maidstone, England) presoak.ed in 0.05% polyeth-
yleneimine. The filters were rinsed three tim~ with the 
same filtration buffer, dried, and the radioactivity 
{bound uacer) counted by liquid scintillation. Non-
specific binding was defined as e H]NMS binding in the 
presence of 1 pM atropinein the four S)'Stems. 
For eH]NMS binding to human NB-OK 1 cell ho-
97 
mogenates, a 0.25 nM tracer concentration (twofold K 0 
in this system) was chosen with a hornogenate con-
centration of 160-200 p.g protein per assay (about 50 
pM binding sites) and an incubation period of 2 h at 
25 ° C allowing fulJ equilibration of tracer binding. 
In binding experiments on rat cardiac homogenates. 
a 1 nM eff)NMS concentration (two-fold K 0 in this 
system) was selected with a homogenate concentration 
of 400-500 f.Lg protein per assay (about 250 pM binding 
sites) and a 2 h incuba; ion period at 25 o C allowing full 
equilibration of tracer binding. 
In binding experiments on rat cortex or striatum 
homogenates. the tracer concentration was 0.25 nM and 
the protein concentration 30-40 p.g per assay (about 50 
pM binding sites). Under equilibrium conditions (2 h 
incubation at 25°C), [3H]NMS Iabelied M1, M3 and M4 
sites in these two brain regions. In order to analyze 
tracer binding to brain M 4 sites only, we chose the 
striatum, which possesses fewer M 1 and M 3 receptors 
than other forebrain areas (Waelbroeck et al., 1990). We 
preincubated striatum homogenates for 2 h at 25 o C tn 
allow equilibrium binding, then induced tracer dissocia-
tion by adding 1 J.LM atropine. eHJNMS dissociated 
from its binding sites after 35 min of isotopic dilution, 
the residual binding being about 30% of initial binding. 
Since eHJNMS dissociation from MI sites is faster than 
that from M 3 and M4 sites, 85% of this residual 
eH]NMS binding corresponded to M 4 binding sites. It 
is necessary to keep tracer binding below 15% of the 
total tracer added to avoid distorsions of the competi-
tion curves due to tracer or unlabelled drug depletion. 
This means that tracer binding to striatum M4 sites in 
the abscnce of unlabelled drug must be rnaintained 
below 5% of the total tracer added (i.e., 30% of the 15% 
initial bindinf>· We therefore decided to use a compara-
tively high [ H}NMS concentration (0.25 nM. equiv-
alent to five-fold K 0 at M4 sites) for these experiments. 
In binding experL'11ents on rat pancreas homogenates 
we used 980 111 of the homogenate per 1.2 rnl sample. 
The eH}NMS concentration was 0.25 nM (two-fold K 0 
in trus system) and protein concentration 800-1000 p.g 
per assay (about 50 p!\.·f bindiPg sites). An incubation 
period of 4 h was necessary to allow binding equi-
librium. 
Protein concentration was measured according to 
Lowry et aL (19 51) using bovine serum albumin as 
standard. 
1.3. Data ana~rsis and sratistics 
The competition curves were analyzed using the com-
puter program described by Richardson and Humrich 
(1984), and were compatible with the existence of a 
single receptor type. K 1 values were calculated from 
IC5<1 values using the Cheng and Prusoff (1973) equa-
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tion. The pKi value was defined as -log Ki. Each 
experiment was repeated at least three times. The Stan-
dard deviations of each IC50 value was below 30% of the 
average va)ue in all cases (corresponding to pK, stan-
dard deviations of < 0.1 log unit) and were therefore 
not mentioned in the tables and figures. The data are 
presented as rneans of the indicated nurnber of experi-
ments. 
2.4. Drugs and chemieals 
fHJNMS (74 Cijmmole) was obtained from 
Amersham International (Bucks, EngJand). Atropine, 
polyethyleneimine and bovine serum albumin (Cohn 
fraction V) were obtained from Sigma Chernical Co. (St. 
Louis, MO, U.S.A.). Tissue culture material and media 
were obtained from Gibco (Gent. Belgium). All other 
chemieals were of the highest grade available. 
Hexahydro-sila-difenidol (1 b) and the analogues 
shown in fig. 1 were synthesized in our laboratories 
((R)- and (S)-la: Tacke et al., 1989; lb: Tacke et al., 
1985; 4b: Waelbroeck et al., 1989a; 2, 3, 5. 6. 7 and Sb 
were prepared by analogy to the synthesis of 1 b. unpub-
lished results; (R)- and (S)-8a were prepared by anakgy 
to the synthesis of (R)- and (S)-la, unpublished results; 
the quaternary ammonium compounds (R)- and (S)-4a, 
(R)- and (S)-9a as weil as 9b were prepared by quaterni-
zation of the corresponding free amines with methyl 
iodide analogaus to the synthesis of 4b. unpublished 
TABLEI 
resuhs). The enantiomeric purity of the enanliomers of 
la, 4a. Sa and 9a was > 99.7% as detennined on the 
basis of calorimetric analyses (differential scanning 
calorimetry) of (R)- and (S)-la (Tacke et al., 1989) and 
(~.)- and (S)-8a (unpublished results). The experimental 
procedure (Sarge and Cammenga, 1985; Tacke et al., 
198 l. 1989} and data evaluation (Sarge et al., 1988) 
followed the lines described in the literature. 
3. Results 
3.1. General considerations 
All the competition curves obtained in this study 
were compatible with the existence of a single receptor 
subtype in the different preparations with Hili coeffi-
cients not significantly different from unity (nH varied 
between 0.95 and 1.10, with standard deviations below 
or equal to 0.05). This suggested that eH]NMS Iabelied 
in each of the tissues homogeneaus binding sites which 
was not discriminated by the drugs used. 
Competition curves with p-chloro-hexahydro-sila-di-
fenidol (7) were shifted to the right by 0.5 to 1 .0 log 
units in all systems in the presence of bovine serum 
albumin (1% ). This is illustrated in fig. 2 using cortex 
homogenates. Almost 10-fold higher concentrations of 7 
were needed to inhibit eH)NMS binding in this tissue 
when 'fraction V' bovine serum albumin was added to 
Antagonist affinities (pK, values) a of hexahydro-sila-difenidol (lb) and analogues la, 2, 3. 4a, 4b. 5-1, 8a, 8b. 9a and 9b obtained m binding 
studies on homogenates of human NB-OK 1 cells (M1 receptors) as well as rat heart (M 2 receptors), pancreas (M 3 receptors) and striatum (M4 
receptors) in the pre:.ence or absence of 1% bovine serum albumin. a 
Antagonist Human NB-OK 1 Rat heart Rat pancreas Rat striatum M 4 
(R}-la hexahydro-difenido) 8.2 7.0 8.1 7.9 
(S)-la hexahydro-difenidol 6.1 5.8 5.9 6.0 
lb hexahydro-sila-difenidol b 7.8 6.7 7.8 7.9 
2 pyrrolidino analogue of bexahydro-sila-difenidol 8.2 6.9 7.8 7.9 
3 hexamethyleneimino anaJogue of hexahydro-sila·difenidol 7.3 6.4 7.1 7.4 
(R)-4a bexahydro-difenidol methiodide 8.6 8.2 8.1 8.5 
(S)-4a hexahydro-difenidol methiodide 6.5 6.0 5.5 6.1 
4b hexabydro-sila-difenidol methiodide 0 8.8 8.0 8.2 8.6 
5 p-methoxy-hexahydro-sila-difenidol 6.7 5.8 7.0 6.7 
6 o-methoxy-hexahydro-sila-difenidol 6.6 6.1 6.5 7.0 
7 p-chloro-hexahydro-sila·difenidol .: 7.6 6.1 7.6 d 7.6 
(R)-8a p-fluoro-he:<ahydro-difenidol c 7.9 6.7 7.9 
(S)-Sa p-fluoro-hexahydro-difenido) c 5.9 5.6 5.8 
Sb p--fluoro-hexahydro-sila-difenidd c 7.8 6.5 7.8 7.8 d 
(R)-9a p-fluoro-hexahydro-difenidol methiodide c 8.4 7.8 8.2 
(S)-9a p-fluoro-hexahydro-difenidoliLlethiodide c 6.3 5.9 6.2 
9b p-fluoro-hexahydro-sila-difenidol meth.iodide c 8.3 7.6 8.3 
31 pK, values (-log K 1) were measured by competition ~ith eH}NMS binding, as explained in Materials and methods. The numbers show the 
mean estimate for three experiments. Tbe S.O. was approx!mately 0.1 log unit. 
b pKi values for lb and 4b in membranes from NB-OK 1 cells, rat hean and rat pancreas were previously published (Waelbroeck et al., I989a). 
c pKi values measured in t!Je al)sence of bovine serum albumin (see text). 
d The competition curves obtained in the presence of bovine serum :llbumin in pancreas and NB-OK 1 homogenates were superimposable, 
suggesting that compounds 7 and Sb had the same affinity for M3 as for M1 receptors. 
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Fig. 2. p-Chloro-heJtahydro-si1a-difenidol (7)-eH]NMS competition 
curves in rat brain cortex homogenates, in the absence (e) or presence 
(O) of 1% BSA (Cohn fraction V) in the incubation buffer. One 
experiment is representative of three performed in duplicate. 
the incubation buffer. This suggested that about 90% of 
compound 7 was bound to bovine serum albumin or a 
contaminant. Similar results were obtained with p-flu-
oro--hexabydro--sila-difenidol (8b) and its methiodide 
(9b) and with the (R)-enanticmers of the corresponding 
carbon analogues 8a and 9a. We therefore determined 
the binding affinities of compounds 7, 8a, 8b, 9a and 9b 
(Fig. 1) to musearlnie receptors in homogenates from 
human NB-OK 1 cells, rat heart and striatum in the 
absence of bovine serum albumin. pKi values are given 
in table 1. 
The binding properties of hexahydro-difenidol (la), 
hexahydro-sila-difenidol (lb) and their analogues 2, 3, 
4a, 4b, 5 and 6 (fig. 1) were hardly affected by inclusion 
of bovine albunrin into the incubation buffer (pKi in-
crease below 0.3 log units). This allowed us to perform 
binding experiments with these compounds in al1 tissues 
in the presence of bovine serum albumin (table 1). 
3.2. Structural variations of rhe amino group 
A comparison of binding affmities of (R)-hexa-
hydro-difenidol ((R)-la), hexahydro-sila-difenidol (1 b) 
and compounds 2/3 and 4aj4b as weil as Saj9a and 
Sb 1 9b outlined the effect of structural variations of the 
cyclic amino (ammonium) group on antimuscarinic 
potency (table 1). Increasing the size of the amino group 
from pyrrolidino to piperidino (2 -+ 1 b) decreased the 
affinity for M1 and (to a lesser extent) M 2 sites. Ex· 
change of the piperidino by the hexamethyleneimino 
group (lb- 3) decreased the affinities for the four 
binding sites. N-Methylation of the silicon compounds 
lb and Sb (- 4b and 9b) increased the affinity for the 
four binding sites, this increase being greatest at M 2 
receptors. This N-methylation effect on the affinity of 
the silicon compounds 1 b and 8b was comparable to or 
greater than the affinity increase observed with the 
corresponding (R}-configurated carbon analogues (R)-la 
(-+ (R)4a) and (R)-8a(- (R)·9a). 
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3.3. Substitutions on the phenylring 
The influence of substituents in the phenyl ring of 
heJtahydro-siJa-difenidoJ (lb) on binding affinity can be 
demonstratcd by comparison of the silicon compounds 
lb, 5, 6, 7 and 8b. as weil as compounds 4b and 9b 
(table 1). Introduction of a methoxy substituent in para 
or ortho position (compounds 5 cmd 6) or a p·chloro 
substituent (7) reduced the affmity to the musearlnie 
receptors up to 16-fold (table 1). The influence of a 
fluoro substituent in para position of hexahydro-sila-
difenidol (1 b - 8b) and its methiodide ( 4b -+ 9b) on 
affinity was moderate. 
3. 4. Sila Substitution 
It was not possible to determine exactly the effect of 
sila substitution on the binding properties of the carbon 
compounds la, 4a. 8a and 9a from the present results. 
We did indeed use the pure enantiomers of 1 a, 4a, 8a 
and 9a in this study but investigated the binding affini-
ties of the racemic mixtures (R/S) of the silicon ana~ 
logues lb, 4b, 8b and 9b (see introduction). The pK 1 
values (table 1) of racemic lb, 4b, 8b and 9b may 
therefore be lower by at most 0.3 log unit than the pKi 
vaJues of their high-affinity enantiomers. This is due to 
the presence of 50% of the low-affmity enantiomers in 
th~ binding assay. 1f this is taken into account. it is 
obvious from table 1 tbat Sild-substitution did not sig-
nificantly affect the binding properties of la, 4a, 8a and 
9a at any subtype. 
3.5. Stereoselectivity 
The effect of N-metbylation of (R)· and (S)-hexa-
hydro-difenidol ((R)- and (S)-la; - (R)- and (S}-4a) 
and (R)- and (S)-p-fluoro-hexahydro-difenidol ((R)- and 
(S)-8a; - (R)- and (S)-9a} on the affinity for the 
muscarinic receptor depended on the receptor subtype 
and on the configuration of the drug (table 2). In 
NB-OK 1 cells (M1 sites), the affmity of both enanti-
TABLE 2 
Stereoselectiv:ity ((R)/(S)) ratios at musearlnie receptor sllbtypes. The 
values shown represent the a.ntilogs of the differences between corre-
sponding mean pKJ values of the (R}- and (S}enantiomers (table 1) 
deterrnined at M 1 receptors in NB-OK 1 cells, M 2 receptors in rat 
beart. as well as M 3 and M4 receptors in rat pancre.as and strialum. 
Stereoselectivity ratios 
MI M~ M3 M, 
Heltahydro-difenidol (la) 130 16 160 79 
Hexahydro-difenido]/methiodide (4a) 130 160 400 250 
p-Fluoro-hexahydro-difenidoi (8a) 100 13 130 
p-Fluoro-hexahydro-difen.idot; 
metlriodide (9a) 130 80 100 
100 
')mers of la and 8a was increased two- to threefold by 
N-methylation (-+ 4a and 9a). In heart (M 2 sites). the 
affinities of the (R)-enantiomers of 1 a and 8a were 
increased 10- to 20-fold by N-methylation (-+ 4a and 
9a) but the affinities of the (S)-enantiomers were almost 
unchanged. ln pancreas (M 3 sites). thc affini•ie~ of 
(R)-hexahydro-difenidol ((R)-la) and its rnethiodide 
((R)-4a) were identical but N-methylation decrcased the 
affinity of the {S)-enantiomers {(S)-la-+ (s)-4a). In 
striatum (M4 sites), the affinities of (R)-la. (R)-Sa and 
(S)-8a were increased two- to fourfold by N-methyl-
ation, whereas the affinity of (S)-la was unchanged. 
p-Fluoro Substitution of the enantiomers of hexa-
hydro-difenidol (la) and its methiodide (4a) changed 
only slightly (if at all) their affinities for M 1, M 2 and 
M 4 sites (table 1). This effect did not depend on the 
absolute configuration of the compounds. 
4. Discussion 
The present study investigated the effects of chang-
ing the size of the cyclic amino group (compounds 2 
and 3). introducing substituents in the phenyl ring 
(compounds 5-7, Sb) and N-methylation (compounds 
4b and 9b) of hexahydro-sila-difenidol {lb) as well as 
thc effects of replacing the centrat silicon atom of 
compounds 1 b, 4b, 8b and 9b by a carbon atom ( com~ 
pounds la, 4a, Sa and 9a) on musearlnie binding affin~ 
ity and receptor selecttvity. All :.he compounds tested in 
this work possess a center of chirality ( central silicon or 
carbon) and therefore exist in two enantiomers. We had 
indications that silanols (R 3Si0H) may racemize in 
aqueous solution (Tacke et al., 1987). Thus compounds 
lb, 2-7, 8b, 4b and 9b were studied as racemates. In 
contrast, the carbon compounds la, 4a, 8a and 9a 
(carbinols, R 3C OH) exist in configurationally stable 
enantiomers. We took advantage of this by investigating 
the binding properlies of the individual enantiomers of 
these compounds at musearlnie receptor subtypes. 
4.1. Binding properlies of p-fluoro-hexahydro-sila-difen-
idol 
The binding affinities {pK, values, table 1) obtained 
with most of the hexahydro-sila-difenidol ana1ogues 
correspond closely to their antimuscarinic potencies 
(pA 2 values) determined in functional experiments at 
Mlt M2 and M3 receptors (Lambiecht et al., 1988; 
1989a,b; Eltze et al., 1988). We were therefore particu-
larly interested in d1e binding properties of p-fluoro-
hexahydro-sila-difenidol (Sb) which bcbaved in func-
tional experiments as a se1ective M 3 antagonist (M3 > 
M 1 > M 2 ) ( Lambrecht et al.. 1988. 1989a,b~ Eglen et al., 
1989: Whiting et al., 1989). In this study we did not find 
M 1 muscarinic binding sites with a low affinity for 
p-fluoro-hexahydro-sila-difenidot (Sb) in human neuro-
blastoma NB-OK 1 cells (labelled by (~H]NMS; table 1) 
or in rat brain cortex. hippocampus and striatum homo-
genates Iabeiied by eH)pirenzepine (data not shown). 
In contrast. the pK 1 vaJues of p-fluoro-hexahydro-sila-
difenidol (8b) obtained at cardiac M2 (6.5) and pan-
creas M 3 sites (7.8) were in reasonable agreement with 
the pA 2 values observed in pharmacc!ogical sturlies 
using isolated guinea-pig atria (M 2; 6.0) and ileum (M3~ 
7.S) preparations (Lambrecht et al., 1988, 1989b). 
In fact. compound Sb showed a markedly higher 
affinity for M1 binding sites in this study (pKi = 7.8; 
table 1) as compared to functional M 1 receptors in rat 
ganglia (pA 2 = 7.2). rabbit vas deferens (pA 2 = 6.7) 
(lambrecht et al., 1988. 1989b) or canine femoral (pA 2 
= 7.1) and saphenous vein {pA 2 = 7.1) (Eglen et al., 
1989; Whiting et al., 1989). Our results also contrast 
with the low affinity of Sb in binding studies using 
eH]telenzepine-labelled calf Superior cervical ganglia 
M 1 receptors (Lambrecht et al., 1989a). We do not have 
at present a satisfactory explanation fot these dif-
ferences. Since it was well known that the binding of 
antagonists to muscarinic M 1 receptors is sensitive to 
the ionic conditions in the incubation medium (Freed-
man et al., 1988) we ~ ·neated our binding experi..-11ents 
at M1 receptors in NB OK 1 cells with p-fluoro-hexa-
hydro-sila-difenidol (Sb) using the Tris buffer which 
was used by Lambrecht et al. (1989a and unpublished 
data) in binding studies at M 1 receptors of calf superior 
cervical ganglia. Under these ionic conditions we again 
found on1y high-affinity binding for compound Sb ( data 
not shown) in NB-OK 1 cells. An alternative explana-
tion, that M 1 receptors m ganglia and rabbit vas de-
ferens aredifferent frorn M1 receptors in rat brain and 
human NB-OK 1 cells seems also unlikely. All the oth~r 
compounds investigaled in this and other studies {in-
cluding the closely related campounds Sa and 9bj b<!d 
similar affinities for the M 1 binding sites of rat brain 
and human NB-OK l cells and for the functional {rab-
bit vas deferens and ganglia) M1 receptors (Waelhroeck 
et al., 1989a; tarnbrecht et al., 1988; 1989a,b; Eltze et 
al., 1988; Feifel et al., 1990; Lambrecht et al., unpub-
lished results). 
4.2. Structure-selectivity relatio;uhips 
When comparing the .structure-binding relationship 
of hexahydro-süa-difenicol analogues to muscarinic re· 
ceptor subtypes. these musearlnie antagonists showed 
some quantitative and qualitative differences in receptor 
selectivity profiles (table 1). 
The influenee of the ring size of the eyelie amino 
group on binding affinity and selectivity ean be demon-
strated by eomparison of compounds 1 b, 2 and 3. I t is 
obvious from the data in table 1 that ti•c affinity to the 
four musearlnie receptor subtypes depends on the strue-
ture of the heterocyclie ring and varies up to fivefold. 
Compound 2, possessing a pyrrolidino ring shows nearly 
the same affinity for the four musearlnie receptors as 
the parent compound hexahydro-sila-difenidol (lb). In 
eontrast, ring extension to the hexamethyleneimino ana-
logue 3 results in a deciease in affinity, this decrease 
being greatest at M 3 receptors. However, the influence 
of the size of the eyelie amino group on receptor selee-
tivity is moderate as compounds 2 and 3 showed ebout 
the same selectivity pattem as the parent compound lb: 
MI = M3 = M4 > M2. 
N-Methylation of (R)-hexahydro-difenidol ((R)-la 
-+ (R)-4a), hexahydro-sila-difenidol (lb-+ 4b), (R)-p-
fluoro-hexahydro-difenidol ((R)-8a-+ (R}-9a] and p-flu-
oro-hexahydro-sila-difenidol (8b-+ 9b) inereased the af-
finity for M1, M 2 and M4 receptors up to 20-fold, this 
inerease being consistently greatest at M2 receptors. In 
contrast, the affinity of compound (R)-la for M 3 recep-
tors in pancreas was not ehanged by N-methylation, 
and that of lb was inereased only 2.5-fold. Thus, N-
methylation of the tertiary amines (R)-la. lb, (R)-8a 
and 8b changed the receptor selectivity pattern from 
M 1 = M 3 = M 4 > M 2 to M 1 ~ M 4 > M 3 = M 2 reeep-
tors, abolishing the selectivity between M2 and M 3 
receptors. It is interesting to note that the binding 
affinities of (S)-la and (S)-8a were only slight1y affected 
by N-methylation at all muscarinic receptor subtypes. It 
is generally assumed that tertiary antimuscarinic agents 
interaet in their protonated form with these receptors 
(Barlow and Chan, 1982; Asselin et al., 1983). N-Meth-
ylation probably does not change the overall charge of 
the cationic head of the compounds studied: steric 
faetors due to the presence of an additional N-methyl 
group may play an important role in the interaction of 
the quatemary compounds 4a, 4b, 9a and 9b with 
musearlnie receptors. 
We also investigated in this study the effe::.r of Sub-
stitution of the phenyl ring in the para and crtho 
positions. The derivatives of hexahycro-sila-difenidol 
and hexahydro-difenidol and of their metmodides tested 
bad equal or lower affinities than the parent compounds 
(table 1) at the four subtypes. The affinity decreases 
might be due to steric bindrance, modification of the 
electron distribution of the molecules, or botb. It is 
interesting in this respect that the affinities of com-
pounds (R)-laj(R)-.8a, (S)-la/(S)-8a, lbj8b, (R)-
4aj(R) = 9a and (S)-4aj(S)-9a were very similar, re-
gardless of the receptor subtype (M1, M 2, l'vf4 ) studied 
and of tbe absolute drug configuration. In contrast, 9b 
bad a two- to threefold lower affinity than 4b for M1, 
M2 and M 4 receptors. This supports the view that the 
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drug position in the muscarinie binding site is adapted 
depending on the aetual drug structure, and is not 
necessarily identical when comparing tertiary and 
quatemary analogues or C3rbon/silicon bioisosters. 
It is noteworthy that the affinity decrease due lo 
p-chloro substitution (lb _. 7) was greatest at M 2 recep-
tors. Thus, the p-chloro analogue 7 shows a greater 
selectivity (30-fold) for M1/M3/M 4 receptors over ~12 
receptors tnan the parent compound lb. o-Metho>.")'-
hexahydro-sila-difenidol (6) presented a unique selectiv-
ity profile. It rec.ogzüzed preferentially tbe M 4 recep-
tors, bad an intermediate affmity for M 1 and M 3 recep-
tors and lowest affinity for M 2 receptors. 
In general, the (R)-enantiomers of compounds 1 a. 4a. 
8a and 9a showed higher binding affinities (up to 398-
fold) for the four musearlnie receptor subtypes than the 
corresponding (S)-configurated isomers (table 1). How· 
ever, this stereoseleetivity was not the same for all 
receptor subtypes. The stereoselectivity ratios (table 2) 
for the t~'Ttiary eompounds hexahydro-difenidol {la) 
and its p-fluoro analogue 8a consistently show the same 
order: M 1 = M":: M 4 > M 2• This implies that the 
stereochemical requirements of the musearlnie M2 re-
ceptors are less stringent than that of the other subtypes 
for the enantiomers of Ja and 8a. Similar resu1ts have 
been obtained with the enantiomers of other tertiary 
antimuscarinics such as trihexiphenidyl. hexbutinol, 
telenzepine or biperiden (for a recent review, see 
Lambrecht et al.. 1989a; Waelbroeck et al, 1989b). The 
stereoselectivity ratios for the tv.·o quaternary com-
pounds 4a and 9a at M 2 receptors are very sirnilar to 
those of the other subtypes. This is mainly due !o th~ 
stereoselective effect of N-methylation on the affmity of 
the (R}-enantiomers of compounds ia and 8a. 
In eonc1usion, this report deseribes strueture-activity 
relationships (induding stereochemical aspeets) of 
muscarinic antagonists related to hexahydro-sila-difen-
idol (lb). All compounds behaved as competitive inhibi-
tors of eH]-N-methylscopolamine binding al MI recep-
torsinhuman neuroblastoma NB-OK 1 cells. r"1z recep-
tors in rat heart as weil as M 3 and M 4 receptors in rat 
pancreas and striatum, respectiveiy. The binding affin-
ity and receptor selectivity in this series of compounds 
was fcund to be controlled by the structure of the cyclic 
amino (arnmonium} group. the substitution pattem of 
the phenyl moiety and the absolute configuration of the 
chiral carbinols la, 4a, 8a and 9a. There was little 
influence of sila-substitution (carbonjsillicon exchange) 
on binding affinity of these chiral compounds. In con· 
trast to pharmacological sturlies using isolated organs 
~uch as rabbit vas deferens, rat gangiia and canine veins 
as well as to binding studies in calf ganglia, we could 
not use p.fluoro-hexahydro-sila-difenidol (8b) to dis-
criminate M3 from M 1 binding sites, due to the high 
affinity of this antirnuscarinic agent for M1 binding sites 
in homogenates of Nß..OK 1 cells and rat brain. 
102 
A-cknowledgements 
M.W .• J.C.. M.T. and J.C. thank the Fund for Med1cal Scit!ntific 
Research (Belgium) for grant 3.4571.85. R. T. thanJ;s the Deutsche 
Forschungsgemeinschaft, and G.l.. E.M. and R.T. rhank thc Fond.-. 
cler Chemischen Industrie (f.R.G.) for fmaocial support. 
References 
Akiba. 1 .• T. Kubo. A. Maeda. H. Bujo. J. Nakai. M. Mishina and S. 
N uma. 1988. Primary structure of porcine muscarinic acetylcho-
line receptor III and antagonist binding studies. FEBS Lett. 235. 
257. 
Asselin. J .. M. Waelbr~k. P. Robberecht. P. De Neer and J. Chris-
tophe. 1983. Effect of pH on binJing of agonists and antagonists 
to rat beart muscarinic receptors. Biocbem. J. 216. 11. 
Barlow. R.B. and M. Chan. 1981. The effects of pH on the affinity of 
pirenz.epine for musearlnie receptors in the guinea-pig ileum and 
rat fundus strip. Br. J. Pharmacol. 77. 559. 
Bonner. T.l .. N.J. Buck.Jey. A.C. Young and M.R. lirann. 1987. 
ldentification of a family of musearlnie acetylcholine receptor 
genes. Science 237, 527. 
Buckiey. NJ .• T.J. Bonner. C.M. Bucldey and M.R. Brann. 1989. 
Antagonis.t binding properlies of five clon~d mw.carinic receptors 
exprc:ssed in CHO-K1 cells. Mol. Pharmacol. 35. 469 
Cheng. Y. and W.H. Prusoff. 1973, Relationship betwee•l the inhibi-
tion constant (K,) and the cona:ntration or inhibitor \\ hich causes 
50 per cent inhibiti.oo (I so) of an c::lzymatic reaction. Biochem. 
Pharmacol. 22, 3099. 
Dörje. F.. J. Wess. G. Lambrecht, M.R. Brann and E. Mutsch!er. 
1990. Antagonisten-bindungsstudlen an flinf klonierten Muska-
rinrezeptor-Subtypen (hm1-hm5) exprimiert in CHQ..Kl-zellen. 
Arch. Phann. 323. 707. 
Eglen. R. M_ W.W. Montgomery and C.A. Machado. 1989, Char-
acteriz.ation of muscarinic receptors mediating m-.JOnses in canine 
femoral vein and artery in vitro. Trends Pharrnacol. Sei 1Q (Suppl.). 
107. 
Eltze, M .. G. Gmelin, J. Wess. C. Strohmann. R. Tacke, E. Mut.schJer 
and G. Lambrecht. 1988, Presynaptic musearlnie receptors mediat-
ing inbibition of neuregenie contractions in rabbit vas deferens are 
of the ganglionic M1-type, European J. Pharmacol. 158. 233. 
Feire!. R.. M. Wagner-Röder, C. Strohmann. R. Tadle, M. 
Waelbroeck, J. Christophe, E. Mut.schJer and G. lambrecht. 1990. 
Stereoselective inhibition of musearlnie receptor subtypes by the 
enantiomers of hexahydro-difenidol and acetylenic anaJogues. e~ 
J. Pharmaco1. 99. 455. 
Freedman. S.B., M.S. Beer and E.A. Harley. 1988, Mu.scarinic M1, M 2 
receptor binding. Relationship \\'ith functiona1 erficacy, European 
J. Pbannacol. 156, 133. 
Giachetti, l\., R. Micheletti and E. Monugna. 1986, Cardioselectiv~ 
profile of AF-DX 116. a muscarine M~ receptor antagonist. Life 
Sei. 38. 1663. 
Giraldo. E... R. M.icheletti. E. Montagna. A. Giacheui. M.A. Yigano. 
H. Ladinsky and C. Mclchiorre. 198ß, Dinding and function.al 
characterization or the cardioselecli•·e inuscarinic ancagonist 
methodramine, J. Phannacol Exp. Ther. 244. 10!6. 
Hammer, R .• C.P. Berrie. NJ.M. Birdsall, A.S V. Burgen and E.C. 
HuJme, 1980, Pirenzepine distinguist>es be1ween different sub-
classes of musearlnie receptors, Nature 283, 9C. 
Hammer. R.. E. Giraldo. G.B. Schia~i. f:.. Monferini. and H. I.adiD-
sky. 1986. Binding prome of a novel cardioselective mus:arine 
receptor antagonist. AF-DX 116, to membrar:es of perbberal 
tissues and brain in the rat. Life Sei 38, 1653. 
Lambrecht. G., R. Feifel., B. Forth. C. Strohmann. R. Tacke, ~nd E. 
Mutschler. 1988. p-Fiuoro-hexahydro-sila-difenidol: the first 
M !P·sela·tivr rnu~arinic anta~oni!.t. European J. Phannacol. 152. 
193. 
Lambrecht. G .. R. Feifel. U. Moser. M. Wagner-Röder. L.K Chru. J. 
Camus. !\·l. Tas.tenoy. M. Waelbroeck. C. Strohmann, R. Tru:!<e. 
J.F. Rodnguer. de M1randa. J. Chrstophe and E. Mulschler. 
1989a, Pharmacology or hexahydro-difenidol. hexahydro-sila-dj. 
fl!nidol and related selective musearlnie antagonists. Trends 
Pharmacol. Sei. 10 (Suppl.), tO. 
l.ambrecht. G .. R. Fcifet. M. Wagn~:r-Röder. C. Strotunann. H. Zilch, 
R. Ta~ke. M. Waelhroeck. J. Chril>tophe. H. Boddeke an.:l f_ 
Mutschler. 1989b. Affinity profiles of hexahydro-s•la·dife.n.idol 
analogues at musearlnie receptor subtypes. European J. Pharma-
col. 168. 71. 
Lambrechl. G .. T.P. Friebe. R. Feifel. N. Rettenmayr. M. WaYJer-
Röder. C. Strohmann. R. T ö~~~. and E. Mutschler. 1990, 
Affinitätsprofile von chiralen analoga des Difer- '.:iols and l)ifen-
idol-methiod!ds an Muscarinrezeptor-Subtypen, Arch. Pharm. 323, 
790. 
Lambre(.ht. G .. E. Mct.schler. U. Moser. J. Rioue. M. Wagner, J. 
W~s. G. Gmelin. R. Tacke and H. Zilch. 1987, Heterogencity in 
muscarinic receptors: evidence from pha.nnacologjca1 and electro-
physiolog.icaJ studies with selective antagonists. in: International 
Symposium on Musearlnie Cholinergic Mechanisms. eds. S. Cohen 
and M. Sokolovsky (Freund Pubtishing House Ltd., Tel-Aviv) p. 
245_ 
Laz.areno. S. and F.F. Roberts. 1989. Function.al and bänding studies 
wilh muscarinic M rsubtype selective antagorusts, Br. J. Pharma-
col. 98. 309. 
Levine, R.R. and NJ.M. Birdsall (eds.). 1989, Subtypes of mu.scarinic 
receptors. IV. Trends Pharmacol. Sei. 10 (Suppt.). 
Lov.-ry. O.H .. N.J. Rosebrough, A.L. Farr and R.J. RandaU. 1951, 
Protein measurement with lhe Folin phenol reagent. J. Biol. Chem. 
193. 265. 
Melchiorre. C.. P. Angeli. G. Larr.:.,raht, E. Mut.schler. M.T. Picchio 
and J. Wess. 1987. Antimuscatit.ic action of methoctramine, a new 
cardioselective M-2 muscarinir; receptor antagonist, alone andin 
combination with atropine and gallamine, European J. Phannarol. 
144. 117. 
Michel. A.D., R. Delmendo. E. Stefanich and R.L. Wbiting. 1989. 
Binding characteristics of the muscarinic receptor subtype of the 
NG108-15 ceJJ line. Naun;n-Schmiedeb. Arch. Pharmacol. 340, 
62. 
Micbeletti. R.. E. Montagna and A. Giachetti, 1987, AF-DX 116. a 
cardiosdective n-•lSCarinic antagonist. J. Pharmacol. E:tp. Ther. 
241. 628. 
Mitchi"lson. F .• 1988, M•~scarinic receptor differentiation, PhariiläCOI. 
Ther. 37, 357. 
Mutschier E.. G. 4melin. U. MüSer, J. Wessand G. Lambrechl. 1987. 
Structure·"..;tit.ity relationships of drugs acting selectively at differ-
en! mt•: . ..:arinic receptors. in: Pharmacology, Int. Congr. Series. 
Vol. 750. eds MJ. Rand and C. Raper {Elsevicr Science Pub-
lishers. Amsterdam) p. 67. 
Mut.scb.ler, E., U. Moser. J. Wess and G. lambrecht, 1988. New 
approaches to the subclassification of musearlnie receptors. in: 
Recent ad••ances in Receptor Cbemßtry. cds C M~tchiorre and M. 
Giannelli! (Etsevier Science Publ.!shers. Amsterdam) p. 195. 
Peralta. E.G .. A. Ashkenazi, J.W. Winslow. D.H. Sm.ith, J. 
Rarnachaßdran and DJ. Capoo.. 1987. Distinct primary structures, 
Iigand-binding properlies and tissue-specific expression of fcur 
human muscarinic acetylcboline receptors. EL\ffiO J. 6. 3923. 
Richard.son. A. and A. Humricb, 1984. A microcomputer program for 
the analysis or J'.tdioligand bindiß6 curves and otber dose-.res.ponse 
data. Trends Pharmacol. Sci. 5, 47. 
Sarge. S., S. Bauerecker and H.K. Cammenga, 1988. Calorimetric 
detennination of purity by Stimulation or dsc curves. Thennochim. 
Acta 129. 309. 
Sarge. S. and H.K. Camrnenga. 1985. Calibration of differential 
scuning calorimeters using ~H-/T- and CP-st.andards: E~tendell 
applicalion to t'III.'O instruments, Thennochim. Acta 94. 17. 
Tacke. R.. H. Linoh, L. Ernst. U. Mos.er, E. Mutsch.ler. S. Sarge, H.K. 
Cammenga and G. Lambrecht, 1987, Preparation and properties 
of the enantiomers or the antimuscarinic agent5 sila-procydidine 
and sila-tricyclamol iodide: oplically active silanoh with silicon as 
the Ul<tre cf dürality. Chem. Ber. 120. 1229. 
Tacke, R.. H. Linoh, H. Zilch. J. Wess. U. Moser. E. MuL~hler and 
G. Lambrecht. 1985, Synthesis aod propenies of the selective 
antimuscarinic agent cyclobexylphenyl(3-piperidinopropyl)silano1, 
Liebigs Ann. Chem. 2223. 
Tacke. R.. C. Strohmann, S. Sarge, H.K. Cammenga. D. Schomburg. 
E. ~.futschler and G. Lambrecht. 1989. Preparation and properties 
of the enantiomer5' of the ~Jective antimuscari.nic agem 1-
cydobexyl-l·pbenyl-4-piperidino-1-butanol (hexahydro-difenidol ). 
Liebigs Ann.. Chem. 137. 
Waelbroeck. M .• J. Camus, J. Winand and J. Christophe. 19.87a. 
Difrerent antagonist binding properlies o! rat pancreatic and 
cardiac musearlnie receptors, Life Sei. 41, 2235. 
Wae!broeck. M., J. Camus. M. Tastenoy and J. Christophe. 1988. 80% 
of mu.scarinic receptors expr~ by the NB-OK 1 human neuro-
blastoma cell line show high affinily for pirenzepine and are 
comparable to rat hippocampus M 1 receptors. FEBS Leu. 226. 
287. 
Wac:lbroeck. M .• M. Gillard. P. Robberecht and J. Christophe. 198ib. 
103 
Muscarinic receptor hetero,5eneity in the rat central ncr..--ou!. sy~· 
tem. I. Binding of four sel~t!Ye antagooists to th.ree muscanrnc 
receptor subcla~~: a romparnon ~itb M ~ cardia.c: muscarimc 
receptors of the C type. Mol. Pharmaco!. 32. 91. 
Waelbroeck. M~ M. Tastenc<y. J. Camu!\ and J Christophe.. Js-90. 
Binrlmg of selective antagon1~1" to four mu<.eartnic rt~.:~f!lflf tM1 H' 
M .. ) in rat forebrrun. Mol. Pharmarol. 38. 267. 
Waelbroeck. M .. !\t Tasteno;,. J. Ce1rnu!>. J. Chmtoph\!, C. Stroh-
mann. H. tinoh, H. Zik!l. R. Ta~ke. E. :!\.1ut~chler and G. 
lambrecht. 1989a. Binding and funaional propertio of anli-
muscariru~ of the hexog.clium;sila·hexocydium and he.u.hydro-
diphenidol/hexahydro-sila-dipben.ic-ol type to mu..~c rec....""PlDr 
subtypes. Br. J. Phannacol. 98. 197. 
Waelb-:-oeck. M .• M. Tastenoy. J. Camu~. R. Feife1. E Mut~ler. C 
Strohmann. R. Tacke. G. Lamb:rechl and J. Chriswphe. 1989b. 
Ster~..electivit) of 1he intern.ction of m!iscarinic amagontst.s v.'ilh 
their re.ceptors. Trends Phail1l2col. Sci. 10 CSuppi.J. 65. 
Wess. J .. G. Lambrecht.. E. MutM:h1er. ;\tR. Srann and F. Dö!Je. 
1990. Selectivixy proftle 0f lhe novel muscariric am.agon.i!.t CH-AH 
37 deterrruned by the u~ \>( done.d receptor~ and tsolated Lissue 
preparation~. Br. J. Pharmaccl .. m pre~. 
Wh1ting,. R.L, R.M. E.glen. W.W. Montgomay and C.A. !\1achado. 
1989. Interaction .of p-fluomhe:t<:hydro~.t12~ilferudol {pFHHSiD; <H 
muscarinic reoeptor !'.ubtyp~ in -..itro. Trends Ph.armacc.l. So.. 10 
{Suppl.). 106. 
